Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 15 May 2019
Prostate cancer: diagnosis and management (NG131)Product type:GuidanceProgramme:NICE guidelinePublished date: 9 May 2019
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancerStatus:In developmentProgramme:Medical technologies guidanceExpected publication date: 16 March 2020
Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 August 2020
Darolutamide for treating non-metastatic hormone-relapsed prostate cancer ID1443Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 November 2020
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide for treating metastatic hormone-sensitive prostate cancer [ID1534]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC